What Researchers Did
This study proposed hyperbaric oxygen therapy (HBOT) as a novel supportive treatment for COVID-19 patients.
What They Found
The researchers noted that 5% of COVID-19 patients develop severe symptoms like hypoxaemic respiratory failure, with a mortality rate of about 2.8%, and conventional oxygen therapies often fail to improve oxygenation in these cases. They highlighted that hyperbaric oxygen therapy (HBOT) increases dissolved oxygen in plasma and mitigates tissue inflammation, potentially reducing the effects of cytokine storm.
What This Means for Canadian Patients
For Canadian patients experiencing severe COVID-19 symptoms, hyperbaric oxygen therapy (HBOT) could potentially offer an additional supportive treatment option to improve oxygenation. This approach might be considered when standard oxygen therapies are insufficient, potentially helping to manage severe respiratory complications.
Canadian Relevance
This study has no direct Canadian connection as it was conducted by researchers in India and published in an Indian journal.
Study Limitations
A key limitation is the acknowledged scarcity of existing literature and clinical evidence specifically on hyperbaric oxygen therapy in COVID-19 patients.